By reducing the fibrotic stroma and subsequently enhancing CTL entry, FAK inhibition not only slowed tumor progression but also rendered the previously unresponsive rodent PDAC responsive to PD-1 antagonists [118]. The gene discussed is PTK2; the disease is neoplasm.